RxDoctor Payments Data

Jana Degregoris

Adult Health · White Plains, NYNPI 1972845360

Payments from drug & device makers

$1,064in general payments, 2019–2025

Across 37 payments — averaging $28.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$343
  • Boston Scientific$161
  • Pfizer$158
  • Impulse Dynamics (USA) Inc.$136
  • Boehringer Ingelheim$97
  • Advanced Oxygen Therapy Inc.$41
  • plus $130 from 5 others

What the payments were for

  • Food & beverage$1,064100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,064 in reported general payments places this provider in the 70th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$38,391
Medicare patients
207
Services billed
412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban169$218,538
EntrestoSacubitril/Valsartan28$41,150
XareltoRivaroxaban28$36,686
JardianceEmpagliflozin13$14,294
Repatha SureclickEvolocumab13$6,900
Metoprolol Succinate191$3,485
Rosuvastatin Calcium130$1,679
Diltiazem 24hr Er (Cd)Diltiazem Hcl38$1,466
Ezetimibe62$1,464
Atorvastatin Calcium129$1,433
Valsartan38$1,378
Nebivolol Hcl17$1,308
Amlodipine Besylate134$1,016
Losartan Potassium71$949
Digoxin19$539

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$158$218,538169 claims
NovartisEntresto$29$41,15028 claims
Boehringer IngelheimJardiance$97$14,29413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,828 adult health providers in New York.

Other adult health in White Plains

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →